Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
Other Sizes |
|
ln Vivo |
For the diagnosis and investigation of CDP-l-ribitol pyrophosphorylase A (CRPPA) muscular dystrophy, CDP-ribitol can be utilized [3].
|
---|---|
References |
[1]. Moffatt BA, et, al. Purine and pyrimidine nucleotide synthesis and metabolism. Arabidopsis Book. 2002;1:e0018.
[2]. Salvador-Silva M, et, al. Microglial cells in the retina of Carassius auratus: effects of optic nerve crush. J Comp Neurol. 2000 Feb 21;417(4):431-47. [3]. Tol W, et, al. Cytidine Diphosphate-Ribitol Analysis for Diagnostics and Treatment Monitoring of Cytidine Diphosphate-l-Ribitol Pyrophosphorylase A Muscular Dystrophy. Clin Chem. 2019 Oct;65(10):1295-1306. |
Molecular Formula |
C9H12N3NA3O11P2
|
---|---|
Molecular Weight |
469.12
|
Exact Mass |
468.96
|
CAS # |
34393-59-4
|
Related CAS # |
Cytidine diphosphate;63-38-7
|
Appearance |
Powder
|
SMILES |
C1=CN(C(=O)N=C1N)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)([O-])OP(=O)([O-])[O-])O)O.[Na+].[Na+].[Na+]
|
InChi Key |
JENUKVZGXGULDX-LLWADOMFSA-K
|
InChi Code |
InChI=1S/C9H15N3O11P2.3Na/c10-5-1-2-12(9(15)11-5)8-7(14)6(13)4(22-8)3-21-25(19,20)23-24(16,17)18;;;/h1-2,4,6-8,13-14H,3H2,(H,19,20)(H2,10,11,15)(H2,16,17,18);;;/q;3*+1/p-3/t4-,6-,7-,8-;;;/m1.../s1
|
Chemical Name |
trisodium;[[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] phosphate
|
Synonyms |
CDP; Cytidine 5'-diphosphate trisodium salt
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
H2O : ~250 mg/mL (~532.9 mM)
DMSO : < 1 mg/mL |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (213.17 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
 (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.1317 mL | 10.6583 mL | 21.3165 mL | |
5 mM | 0.4263 mL | 2.1317 mL | 4.2633 mL | |
10 mM | 0.2132 mL | 1.0658 mL | 2.1317 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.